Stock Evaluator: Journey Medical Corporation (DERM)

Journey Medical Corporation DERM

$5.68 -0.23 -3.89%
October 13, 2026 4:00:00 PM EST November 10, 2021 Volume: 200,722
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Commentary & Analysis


Financial Summary

Share Statistics DERM Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $160.3 $492.0 26%
Shares Out (Mil) 27.5 42.8 35%
Institutional Ownership 75.8% 82.8% 46%
Float (Mil) 15.6 44.4 25%
Beta 1.10 0.71 66%
Avg Daily Volume (000s) 177 376 43%
Price Change
(52-week)
(21.2%) 55.3% 34%
Growth DERM Industry
Median
Percentile
(All Stocks)
Sales (5yr) 6.8% 6.1% 45%
Net Income (5yr) (32.9%) (2.0%) 12%
EPS (5yr) (24.2%) 15.0% 11
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (17.0%) (15.1%) 42%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials DERM Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $68 $416 23%
Net Income (TTM) (Mil) ($6) ($11) 32%
EPS (TTM) ($0.228) ($0.700) 33%
Operating Cash Flow (TTM) (Mil) ($8) ($7) 22%
Net Cash Flow (TTM) (Mil) na $5 na
Long-Term Debt (Q1) (Mil) $21 $6 33%
Enterprise Value (Q1) (Mil) $206 $494 26%
Valuation DERM Industry
Median
Percentile
(All Stocks)
P/B 4.90 2.15 79%
P/E na 17.4 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.1 na
Ratios DERM Industry
Median
Percentile
(All Stocks)
Gross Margin 65.5% 69.4% 78%
Net Margin (9.0%) 3.2% 22%
ROA (6.8%) (22.2%) 28%
ROE (23.8%) (21.4%) 22%
Liabilities to Assets 67.3% 32.8% 63%
F-Score 3 3 18%

Journey Medical Corporation did not pass any screens on 10/13/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors